This Bosutinib Isomer differs only in the positions of the chlorines and methoxy substituents on the aniline ring. Often mistaken to be the correct structure of bosutinib.
DOT/IATA TRANSPORT INFORMATION
Not hazardous material
REVIEW Isomer of Bostinub (also known as SK1-606) , a tyrosine kinase inhibitor, undergoing research for use in the treatment of cancer. originally synthesized by Wyeth, it is being developed by Pfizer. Bosutinib received US FDA approval on September 4, 2012 for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.
Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F, Jove R. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther. 2008 May;7(5):1185-94.
Cortes JE, Kantarjian HM, BrCimmendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury Hi, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011 Oct 27418(17):4567-76.
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.